J&J boosts investments in US to more than $55 billion amid looming tariff threats

Johnson & Johnson plans to spend over $55 billion to build four plants in the U.S., it said on Friday, as a threat of drug import duties from the Trump administration forces companies to expand their manufacturing operations domestically.

The new plants will be built over the next four years, including in Wilson, North Carolina, where the pharmaceutical giant officially broke ground on Friday. The drug and device maker said the investment represents a 25% increase compared to the last four years.

Last month, drugmaker Eli Lilly announced its plans to invest in the country, as companies brace for the impact of a potential 25% tariff on pharmaceutical imports.

Companies such as J&J and Pfizer could be at risk as they operate large plants in countries like Ireland, which President Donald Trump said has lured them with its tax policies.

Trump, who campaigned on a promise to boost domestic manufacturing, has been piling pressure on drugmakers since taking office to move medicine production to the United States.

Companies in other sectors, such as iPhone-maker Apple, have also made manufacturing announcements in recent weeks.

J&J’s site in Wilson, where it plans to invest more than $2 billion, is expected to create 5,000 jobs during construction, and more than 500 positions across the state. The site will focus on producing medicines used for treating cancer, immune-mediated and neurological diseases, it said.

The company said it already has more manufacturing facilities in the U.S. than in any other country. It plans to expand several of its existing sites in the U.S. and build new infrastructure for research and technology.

J&J, however, did not disclose details about the expansion plans or the location of its other planned facilities in its statement.